1
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath: Antibodies against human CD40. Bristol Myers Squibb Co, Christopher A Klein, Audrey F Sher, April 18, 2000: US06051228 (81 worldwide citation)

The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent ant ...


2
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath, William D Huse, Herren Wu, Jeffry D Watkins: Antibodies against human CD40. Joan E Switzer, November 6, 2001: US06312693 (21 worldwide citation)

The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transp ...


3
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath: Methods of using antibodies against human CD40. Bristol Myers Squibb Company, Joan E Switzer, July 2, 2002: US06413514 (11 worldwide citation)

A method for the treatment of T cell mediated disorders is described. The method involves administering to a subject a therapeutically effective amount of an anti-human CD40 antibody. Disease states suitable for treatment with this method include graft versus host disease and transplant rejection an ...


4
Pauline McLean Quigley Sheldon, Peter S Gagnon, Gina Nichols, Barbara A Thorne: Methods for purification of recombinant AAV vectors. GENZYME CORPORATION, Morrison & Foerster, July 10, 2018: US10017746

Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production co ...


5

6